Tharimmune announces key leadership appointments including james gordon liddy joining board of directors

Bridgewater, new jersey / access newswire / june 17, 2025 / tharimmune, inc. (nasdaq:thar), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology, today announced significant appointments to its executive leadership and board of directors, reinforcing its commitment to advancing its pipeline and strategic initiatives. the company is advancing its lead candidate th104 specifically designed through a buccal film formulation to deliver an opioid antagonist rapidly and predictably.
THAR Ratings Summary
THAR Quant Ranking